HMG CoA 减少酶抑制剂 (他) 和大动脉的
David M Shavelle1, Junichuro Takasu, Matthew J Budoff
1Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98195-6422, USA.
Lancet (London, England)
|April 12, 2002
概括
类药物可能会减缓甲状腺膜 (AVC) 积累的进展,在患有甲状腺膜疾病的患者中. 这项研究发现,他类药物的使用与AVC积累率和进展的显著降低有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 放射学 放射学是一门学科.
背景情况:
- 甲状腺膜硬化/狭窄缺少药物治疗.
- 大动脉的化与脂蛋白沉积有关.
研究的目的:
- 为了研究3 - 基-3 - 甲基酸 - 同酶A (HMG COA) 减少酶抑制剂 (他类药物) 在减缓大动脉 (AVC) 积累中的潜力.
主要方法:
- 对65名接受两次电子束计算机断层扫描的患者进行了回顾性分析.
- 在服用他类药物和不服用他类药物的患者之间,AVC积累率的比较.
主要成果:
- 服用他类药物的患者显示AVC积累的中位数率降低了62-63% (p=0.006).
- 服用他类药物的患者中,确定的AVC进展率减少了44-49% (p=0.043).
结论:
- 类药物可能代表一种潜在的治疗策略,以减少AVC积累.
- 需要进一步的研究来证实他类药物的有效性,以控制状动脉病.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


